1-5 of 5
Nikki Church
Close
Sort by
Journal Articles

Bay 94-9027 Can be Accurately Measured across Regions with Appropriate One-Stage Assay Reagent Use

Rajiv K. Pruthi, M.B.B.S., Donna D. Castellone, Nikki Church, MD MBA, Lilley Leong, PhD, Steve Kitchen
Journal: Blood
Blood (2018) 132 (Supplement 1): 2481.
https://doi.org/10.1182/blood-2018-99-113493
Published: 2018
Journal Articles

Bay 81-8973 Prophylaxis Frequency and Long-Term Bleed Outcomes in the Leopold I Extension Study

Kapil Saxena, MD MS, Gautam Sajeev, ScD, Rajeev Ayyagari, PhD, Akanksha Dua, BA, Nikki Church, MD MBA, Martin Sanabria, MD, Olubunmi O. Afonja, MD MBA
Journal: Blood
Blood (2017) 130 (Supplement 1): 1076.
https://doi.org/10.1182/blood.V130.Suppl_1.1076.1076
Published: 2017
Journal Articles

Rationale for Investigator-Assigned Prophylaxis Dosing Frequency in the Leopold I Study

Thomas J. Humphries, Nikki Church, Shadan Lalezari, Lone H. Poulsen, Mia Yoon, Monika Maas Enriquez
Journal: Blood
Blood (2016) 128 (22): 4984.
https://doi.org/10.1182/blood.V128.22.4984.4984
Published: 2016
Journal Articles

Bay 94-9027, a Site-Specifically Pegylated Recombinant Factor VIII: Preliminary Results from an International Comparative Laboratory Field Study

Nikki Church, Lilley Leong, Yvonne Katterle, Yadagiri Rao Danda, Hannes-Friedrich Ulbrich, Iris Noerenberg, Stefan Bruns, Lisa A. Michaels
Journal: Blood
Blood (2016) 128 (22): 2587.
https://doi.org/10.1182/blood.V128.22.2587.2587
Published: 2016
Journal Articles

Patterns of Prior Treatment and Bleeds Among Patients with Severe Hemophilia a: Impact on Frequency of Dosing with Bay 81-8973 in the Leopold I Trial

Nikki Church, MD MBA, Rajeev Ayyagari, PhD, Jennifer Pocoski, PharmD, Gautam Sajeev, ScD, Sneha S Kelkar, MPH, Ella X Du, MS, Monika Mass-Enriquez, MD, Jipan Xie, MD PhD
Journal: Blood
Blood (2015) 126 (23): 1103.
https://doi.org/10.1182/blood.V126.23.1103.1103
Published: 2015